CanSino Biologics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CanSino Biologics Inc.
Ocugen’s mutation-agnostic candidate for retinitis pigmentosa and leber congenital amaurosis is set for Phase I trials in the US. In this exclusive audio interview, founder and CEO Shankar Musunuri speaks to Scrip about seeking partners beyond CanSino Biologics for the candidate while stressing Bharat Biotech’s COVID-19 vaccine could hold promise against the Omicron variant.
Nasdaq, Hong Kong and soon Shanghai, major Chinese firm BeiGene will be listed on three stock markets globally. But the high offer price of its imminent debut on China's STAR Market has raised concern among some investments and involved the use of a rare mechanism in the country.
From inactivated virus-based to mRNA platforms, the race is on in China to develop vaccines to fight the latest omicron variant, with substantial new funding pouring into one young mRNA company.
New research by US-based Canadian scientist Michael Worobey sheds further light on the role of the Wuhan market in the human origins of SARS-CoV-2.
- Other Names / Subsidiaries
- Tianjin CanSino Biotechnology